NCT02341014View on ClinicalTrials.gov

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 2, 2015

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions

T-cell LymphomasRelapsed or Refractory

Interventions

DRUG

Carfilzomib

The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .

DRUG

Romidepsin

DRUG

Lenalidomide

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

68198-7680

University of Nebraska Medical Center, Omaha

07920

Memoral Sloan Kettering Cancer Center, Basking Ridge

All Listed Sponsors

collaborator

University of Nebraska

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02341014 - Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas | Biotech Hunter | Biotech Hunter